NeuroOne Medical Technologies (NASDAQ:NMTC) Announces Earnings Results

NeuroOne Medical Technologies (NASDAQ:NMTC) released its quarterly earnings data on Tuesday. The company reported $0.04 earnings per share for the quarter, FiscalAI reports. The firm had revenue of $2.74 million for the quarter. NeuroOne Medical Technologies had a negative net margin of 55.44% and a negative return on equity of 163.49%.

NeuroOne Medical Technologies Stock Performance

NASDAQ:NMTC opened at $0.71 on Wednesday. NeuroOne Medical Technologies has a 52 week low of $0.40 and a 52 week high of $1.39. The firm has a 50-day moving average price of $0.74 and a two-hundred day moving average price of $0.77. The firm has a market cap of $35.34 million, a price-to-earnings ratio of -4.71 and a beta of 0.71.

Institutional Trading of NeuroOne Medical Technologies

Institutional investors and hedge funds have recently modified their holdings of the business. Goldman Sachs Group Inc. bought a new position in NeuroOne Medical Technologies in the 1st quarter valued at $84,000. Sio Capital Management LLC purchased a new position in shares of NeuroOne Medical Technologies in the 2nd quarter worth about $2,390,000. Warberg Asset Management LLC purchased a new position in shares of NeuroOne Medical Technologies in the 2nd quarter worth about $27,000. Vanguard Group Inc. grew its position in NeuroOne Medical Technologies by 31.2% during the third quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after buying an additional 375,639 shares during the period. Finally, Virtu Financial LLC purchased a new stake in NeuroOne Medical Technologies during the third quarter worth about $88,000. 16.07% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently weighed in on NMTC shares. Maxim Group started coverage on shares of NeuroOne Medical Technologies in a report on Tuesday, September 9th. They issued a “buy” rating and a $3.00 target price on the stock. Wall Street Zen raised NeuroOne Medical Technologies to a “hold” rating in a report on Friday, October 3rd. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of NeuroOne Medical Technologies in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $2.23.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corporation, a developmental stage company, provides solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson’s disease, dystonia, essential tremors, and chronic pain due to failed back surgeries and other related neurological disorders.